recently closed trials

EORTC 62061 – Randomised phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma.

EORTC 62024 – a trial looking at intermediate and high risk localised, completely resected, gastrointestinal stromal tumours (GIST) expressing KIT receptor : a randomized controlled trial of adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery.